Simulations Plus Upgrades PKPlus™
July 09 2019 - 8:30AM
Business Wire
Enhancements include improved data handling
and command line functionality
Simulations Plus, Inc. (Nasdaq: SLP), the leading provider of
modeling and simulation solutions for the pharmaceutical,
biotechnology, chemicals, and consumer goods industries, today
announced the launch of version 2.5 of PKPlus, an update to its
software for analysis of preclinical and clinical trial data.
Mark Pflieger, product manager for PKPlus, said: “We delivered
several important enhancements, including the simplification of
pharmacokinetic (PK) data analyses, as well as automating and
streamlining key routines. Special thanks to the dedicated team at
Simulations Plus and those clients that provided important feedback
for all their efforts.”
New features and enhancements of PKPlus 2.5 include:
- Import CDISC SEND packages with PC domain as source data
- Improved command line functionality
- 64-bit system optimization for improved performance
- Streamlined auto-reports
- Additional workflow refinements
John DiBella, president of the Lancaster division for
Simulations Plus, added: “As the client base for PKPlus has grown,
we have engaged with users to identify the core functionality that
they need to support the vast majority of their research
activities. Throughout this effort, we’ve been, and continue to be,
laser-focused on making our clients’ jobs easier with the
enhancements in this new release. The demand for an affordable,
commercially supported PK modeling platform remains strong, and we
look forward to getting this version into the hands of industry
scientists and students alike.”
View on demand the exciting new features in PKPlus 2.5 in the
webinars section of the Simulations Plus website. In our commitment
to support future generations of PK modelers, we continue to offer
this version at no cost for academic institutions.
About Simulations Plus, Inc.
Simulations Plus, Inc., is a premier developer of drug
discovery/development software and a leading provider of both
preclinical and clinical pharmacometric consulting services for
regulatory submissions and quantitative systems pharmacology models
for drug-induced liver injury, drug-induced kidney injury, and
nonalcoholic fatty liver disease. Our software is used to conduct
drug research by major pharmaceutical, biotechnology, chemical,
consumer goods companies and regulatory agencies worldwide. Our
innovations in integrating new and existing science in medicinal
chemistry, computational chemistry, pharmaceutical science,
biology, and physiology into our software have made us the leading
provider for physiologically based pharmacokinetic modeling and
simulation. Visit us online www.simulations-plus.com.
Safe Harbor Statement Under the Private Securities Litigation
Reform Act of 1995 – With the exception of historical
information, the matters discussed in this press release are
forward-looking statements that involve a number of risks and
uncertainties. Words like “believe,” “expect” and “anticipate” mean
that these are our best estimates as of this writing, but that
there can be no assurances that expected or anticipated results or
events will actually take place, so our actual future results could
differ significantly from those statements. Factors that could
cause or contribute to such differences include, but are not
limited to: our ability to maintain our competitive advantages,
acceptance of new software and improved versions of our existing
software by our customers, the general economics of the
pharmaceutical industry, our ability to finance growth, our ability
to continue to attract and retain highly qualified technical staff,
our ability to identify and close acquisitions on terms favorable
to the Company, and a sustainable market. Further information on
our risk factors is contained in our quarterly and annual reports
and filed with the U.S. Securities and Exchange Commission.
Follow us on Twitter | LinkedIn
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190709005333/en/
Simulations Plus Investor Relations
Ms. Renee Bouche 661-723-7723 renee@simulations-plus.com
Hayden IR Mr. Cameron Donahue
651-653-1854 cameron@haydenir.com
Simulations Plus (NASDAQ:SLP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Simulations Plus (NASDAQ:SLP)
Historical Stock Chart
From Apr 2023 to Apr 2024